A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral EGFR tyrosine kinase inhibitor, shows supra-additive growth inhibition with irinotecan and fluoropyrimidines in xenograft models. We designed a study to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Veronese, M L, Sun, W, Giantonio, B, Berlin, J, Shults, J, Davis, L, Haller, D G, O'Dwyer, P J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361767/
https://www.ncbi.nlm.nih.gov/pubmed/15870719
http://dx.doi.org/10.1038/sj.bjc.6602569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361767/
https://www.ncbi.nlm.nih.gov/pubmed/15870719
http://dx.doi.org/10.1038/sj.bjc.6602569

Ejemplares similares